Janssen terminates izencitinib deal with Theravance Biopharma

seekingalpha2021-12-23

In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYSE:JNJ)company has terminated its agreement with the company. In 2018,TBPH entered into a License and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

ReginHeng
2021-12-23
ReginHeng
Great
ivy888
2021-12-23
ivy888
Like
Stchua
2021-12-23
Stchua
[Smile]
Stchua
2021-12-23
Stchua
Like please
stormlee
2021-12-23
stormlee
Pls like tks 😊

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117601455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-12-23 16:35","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1117601455","market":"us","top_or_hot":-1,"title":"Janssen terminates izencitinib deal with Theravance Biopharma","media":"seekingalpha","content":"<div>\n<p>In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYSE:JNJ)company has terminated its agreement with the company.\nIn 2018,TBPH entered into a License and...</p>\n\n<a href=\"https://seekingalpha.com/news/3782899-janssen-terminates-izencitinib-deal-with-theravance-biopharma\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janssen terminates izencitinib deal with Theravance Biopharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanssen terminates izencitinib deal with Theravance Biopharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 16:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3782899-janssen-terminates-izencitinib-deal-with-theravance-biopharma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYSE:JNJ)company has terminated its agreement with the company.\nIn 2018,TBPH entered into a License and...</p>\n\n<a href=\"https://seekingalpha.com/news/3782899-janssen-terminates-izencitinib-deal-with-theravance-biopharma\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TBPH","symbol_name":"Theravance Biopharma Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3782899-janssen-terminates-izencitinib-deal-with-theravance-biopharma","article_id":"1117601455","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117601455","pubTimestamp":1640248518,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYS","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TBPH":"Theravance Biopharma Inc.","JNJ":"强生"},"translate_title":"杨森终止与Theravance Biopharma的izencitinib交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9,"TBPH":0.9},"content_text":"In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYSE:JNJ)company has terminated its agreement with the company.\nIn 2018,TBPH entered into a License and Collaboration Agreement with Janssen Biotech for izencitinib and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis (UC) and Crohn’s disease.\nIn August 2021, the Company completed a Phase 2b/3 study of izencitinib in UC and failed to meet its primary endpoint.\nIn November 2021, Theravance Bio announced that it voluntarily discontinued its Phase 2 study of izencitinib in Crohn’s disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9000490105,"gmtCreate":1640252162479,"gmtModify":1676533512005,"author":{"id":"3586040211592467","authorId":"3586040211592467","name":"ReginHeng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586040211592467","authorIdStr":"3586040211592467"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000490105","repostId":1117601455,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":691747052,"gmtCreate":1640251771883,"gmtModify":1676532433099,"author":{"id":"3579641974902127","authorId":"3579641974902127","name":"ivy888","avatar":"https://static.tigerbbs.com/10358949b7fc96b011ec29ca7fd9c9a4","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579641974902127","authorIdStr":"3579641974902127"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/691747052","repostId":1117601455,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9000403779,"gmtCreate":1640250538605,"gmtModify":1676533511824,"author":{"id":"3586774718687945","authorId":"3586774718687945","name":"Stchua","avatar":"https://static.tigerbbs.com/9c6da38be819096178bf3d64e02165e0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586774718687945","authorIdStr":"3586774718687945"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000403779","repostId":1117601455,"repostType":4,"repost":{"id":"1117601455","kind":"news","pubTimestamp":1640248518,"share":"https://ttm.financial/m/news/1117601455?lang=&edition=fundamental","pubTime":"2021-12-23 16:35","market":"us","language":"en","title":"Janssen terminates izencitinib deal with Theravance Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1117601455","media":"seekingalpha","summary":"In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYS","content":"<p>In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson &amp; Johnson(NYSE:JNJ)company has&nbsp;terminated its agreement with the company.</p>\n<p>In 2018,TBPH entered into a License and Collaboration Agreement with Janssen Biotech&nbsp;for izencitinib and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis (UC) and Crohn’s disease.</p>\n<p>In August 2021, the Company completed a Phase 2b/3 study of izencitinib in UC and&nbsp;failed to meet its primary endpoint.</p>\n<p>In November 2021, Theravance Bio announced that it voluntarily discontinued its&nbsp;Phase 2 study of izencitinib in Crohn’s disease.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Janssen terminates izencitinib deal with Theravance Biopharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJanssen terminates izencitinib deal with Theravance Biopharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 16:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3782899-janssen-terminates-izencitinib-deal-with-theravance-biopharma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYSE:JNJ)company has terminated its agreement with the company.\nIn 2018,TBPH entered into a License and...</p>\n\n<a href=\"https://seekingalpha.com/news/3782899-janssen-terminates-izencitinib-deal-with-theravance-biopharma\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","TBPH":"Theravance Biopharma Inc."},"source_url":"https://seekingalpha.com/news/3782899-janssen-terminates-izencitinib-deal-with-theravance-biopharma","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1117601455","content_text":"In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYSE:JNJ)company has terminated its agreement with the company.\nIn 2018,TBPH entered into a License and Collaboration Agreement with Janssen Biotech for izencitinib and related back-up compounds for inflammatory intestinal diseases, including ulcerative colitis (UC) and Crohn’s disease.\nIn August 2021, the Company completed a Phase 2b/3 study of izencitinib in UC and failed to meet its primary endpoint.\nIn November 2021, Theravance Bio announced that it voluntarily discontinued its Phase 2 study of izencitinib in Crohn’s disease.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000403204,"gmtCreate":1640250441816,"gmtModify":1676533511831,"author":{"id":"3586774718687945","authorId":"3586774718687945","name":"Stchua","avatar":"https://static.tigerbbs.com/9c6da38be819096178bf3d64e02165e0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586774718687945","authorIdStr":"3586774718687945"},"htmlText":"Like please&nbsp;","listText":"Like please&nbsp;","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000403204","repostId":1117601455,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000577276,"gmtCreate":1640249035308,"gmtModify":1676533511744,"author":{"id":"3571959390768435","authorId":"3571959390768435","name":"stormlee","avatar":"https://static.tigerbbs.com/80629ef9648273c0d6465aee66dbd98a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571959390768435","authorIdStr":"3571959390768435"},"htmlText":"Pls like tks 😊","listText":"Pls like tks 😊","text":"Pls like tks 😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000577276","repostId":1117601455,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":40,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117601455"}